Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Molecular and Pharmacogenetic Marker Evaluation in Relation to the Toxicity and Clinical Response of Acute Lymphoblastic Leukemia Treatment in Indian Children (MPGx-INDALL)

NCT05512169 is registered in ClinicalTrials.gov with University of Geneva, Switzerland as lead sponsor.

NCT NCT05512169
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05512169 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Molecular and Pharmacogenetic Marker Evaluation in Relation to the Toxicity and Clinical Response of Acute Lymphoblastic Leukemia Treatment in Indian Children (MPGx-INDALL)
Lead sponsor
University of Geneva, Switzerland
Phase
Observational
Overall status
Recruiting
Start date
December 1, 2022
Completion date
March 30, 2027
Enrollment
556 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

adverse drug event, all, childhood, drug effect, drug interaction, drug toxicity, pediatric cancer, relapse leukemia, toxicity, drug